HIV

Less than 10% of young gay, bisexual, and other men who have sex with men have used HIV pre-exposure prophylaxis.

An individual’s life expectancy after initiating therapy differs among high and middle/low-income countries.

Navigating prior authoization requirements for patients coinfected with hepatitis C and HIV remains a challenge.

HIV Test-and-Treat initiates antiretroviral therapy promptly, but may be too expensive to employ nationwide.

Some individuals produce antibodies that can recognize HIV.

When combining 2 complicated drug regimens, pharmacists have the opportunity to impact the lives of organ transplant patients and prevent adverse outcomes.

HIV can increase hospitalization for mental health issues compared with the general population.

Inhibiting immune cells’ oxygen-sensing capability prevented lung metastasis in mice.

Insight into the inner complexities of HIV and cytotoxic T lymphocyte evolution raise hopes for HIV cure.

Therapies that target certain gut bacteria may prevent complications and improve the efficiency of antiretroviral therapy.

Investigators at ViiV Healthcare are analyzing a 2-drug regimen of dolutegravir and lamivudine for HIV.

United Nations Program on HIV and AIDS seeks to reach 90% of HIV patients administered antiretroviral therapy to achieve durable viral suppression.

Research reveals potential drug targets for cervical cancer associated with human papillomavirus.

Bioethicist calls attention to urgent need for HIV treatment efforts in pregnant women worldwide.

Transmission rates reduced 96% among couples who both received treatment.

National Institutes of Health awards $9.4 million to improve HIV health care.

Researchers reveal how anti-HIV inhibitors bind to the wrong target.

Researchers seek to reduce the significant HIV risk among homeless people.

The combination of emtricitabine/tenofovir alafenamide did not show a treatment benefit over comparator therapies.

Early treatment for HIV and tuberculosis found to improve outcomes.

Findings point to need to target only non-damaged HIV in the body.

The transgender community includes a plethora of patients who can benefit from HIV/AIDS research. However, clinical trials rarely include transgender participants.

Patients administered PRO 140 monotherapy reach 2 years of complete remission in trial.

Study targets how HIV avoids immune system defenses.

Research evaluates how HIV evades immune system detection.